N

Novavax
D

NVAX

7.98000
USD
0.06
(0.69%)
مغلق
حجم التداول
415,865
الربح لكل سهم
1
العائد الربحي
-
P/E
-4
حجم السوق
1,278,276,252
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    AEMD
    -0.01550
    (-2.58%)
    0.58640 USD
    A
    ALT
    -0.19000
    (-2.87%)
    6.42000 USD
    AZN
    AZN
    -0.350
    (-0.47%)
    74.220 USD
    BNTX
    BNTX
    2.240
    (1.90%)
    120.100 USD
    C
    CODX
    0.01720
    (2.46%)
    0.71700 USD
    I
    INO
    0.02000
    (0.91%)
    2.23000 USD
    JNJ
    JNJ
    2.680
    (1.68%)
    162.370 USD
    MRK
    MRK
    1.820
    (2.08%)
    89.500 USD
    MRNA
    MRNA
    1.785
    (5.29%)
    35.535 USD
    PFE
    PFE
    0.405
    (1.56%)
    26.305 USD
    V
    VXRT
    0.00670
    (0.95%)
    0.70980 USD
    المزيد
الأخبار
المقالات

العنوان: Novavax

القطاع: Healthcare
الصناعة: Biotechnology
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.